| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| 10mg | |||
| Other Sizes |
| Targets |
Docetaxel Impurity; Docetaxel intermediate; tubulin
10-Oxo Docetaxel targets microtubules, similar to other taxanes, by promoting tubulin polymerization and stabilizing microtubules, thereby disrupting mitotic spindle function and causing cell cycle arrest. As a docetaxel intermediate and impurity, it is used in research related to taxane chemistry and anti-tumor activity. |
|---|---|
| ln Vitro |
10-Oxo Docetaxel demonstrates in vitro anti-tumor cell line properties. As a novel taxoid, it has remarkable anti-tumor properties. The compound is used as a docetaxel intermediate in research. Purity is typically >93%.
|
| ln Vivo |
In vivo, 10-Oxo Docetaxel is a docetaxel intermediate with anti-tumor properties. As a taxane derivative, it may share some pharmacological properties with docetaxel. Further in vivo studies would be required to fully characterize its anti-tumor activity and therapeutic potential.
|
| Enzyme Assay |
In vitro tubulin polymerization assays for 10-Oxo Docetaxel typically employ purified tubulin and measure polymerization by monitoring turbidity at 340 nm. Microtubule stabilization is assessed by evaluating the ability of the compound to promote tubulin polymerization and stabilize pre-formed microtubules against cold-induced depolymerization.
|
| Cell Assay |
In vitro cellular assays for 10-Oxo Docetaxel involve treating cancer cell lines with varying concentrations of the compound (typically 0.001-100 microM range) for 24-72 hours. Readouts include cell viability measured by MTT or CellTiter-Glo assays, assessment of cell cycle distribution by flow cytometry, evaluation of mitotic spindle morphology by immunofluorescence microscopy, and assessment of apoptosis.
|
| Animal Protocol |
In vivo animal studies for 10-Oxo Docetaxel would typically employ xenograft mouse models bearing human tumor cell lines. Tumor-bearing mice would be administered the compound via appropriate routes at various doses. Tumor growth inhibition would be monitored over 2-4 weeks. Endpoints would include tumor volume, body weight, survival, and pharmacodynamic biomarkers of microtubule inhibition.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 10-Oxo Docetaxel would be similar to other taxanes. As a docetaxel impurity and intermediate, its PK profile would be determined via LC-MS/MS analysis following administration in appropriate animal models. The compound is a taxane derivative with a molecular weight of 805.86.
|
| Toxicity/Toxicokinetics |
10-Oxo Docetaxel is a research-grade compound for laboratory use only. As a taxane derivative, appropriate safety precautions should be observed during handling including PPE and work in a fume hood. The compound is not intended for human therapeutic use. Comprehensive toxicology data is not publicly available.
|
| Additional Infomation |
10-Oxo Docetaxel (CAS# 167074-97-7) is a novel taxoid with anti-tumor properties and a docetaxel intermediate/impurity. It is also known as Docetaxel Impurity 1 or 6-Oxodocetaxel. The compound is not approved for clinical use and is for research purposes only.
|
| Molecular Formula |
C43H51NO14
|
|---|---|
| Molecular Weight |
805.863340000001
|
| Exact Mass |
805.33
|
| CAS # |
167074-97-7
|
| PubChem CID |
15200439
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
887.3±65.0 °C at 760 mmHg
|
| Flash Point |
490.4±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.614
|
| LogP |
6.29
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
58
|
| Complexity |
1700
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
CC1=C2C(=O)C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C
|
| InChi Key |
ZOLQDWANVNOXBK-YYCGEXIESA-N
|
| InChi Code |
InChI=1S/C43H51NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30,32-33,35,46,48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,32+,33-,35-,41+,42-,43+/m0/s1
|
| Chemical Name |
[(1S,2S,3R,4S,7R,9S,10S,15S)-4-acetyloxy-1,9-dihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11,12-dioxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
|
| Synonyms |
6-Oxodocetaxel; 10-Oxo Docetaxel; 167074-97-7; Docetaxel Impurity B; 10-Deoxy-10-oxodocetaxel; UNII-VB305F5FMZ; VB305F5FMZ; Docetaxel trihydrate impurity B [EP];
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2409 mL | 6.2046 mL | 12.4091 mL | |
| 5 mM | 0.2482 mL | 1.2409 mL | 2.4818 mL | |
| 10 mM | 0.1241 mL | 0.6205 mL | 1.2409 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
